D. E. Shaw & Co., Inc. Exelixis, Inc. Transaction History

D. E. Shaw & Co., Inc.

$114 Billion
Q1 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Exelixis, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 529,493 shares of EXEL stock, worth $11.6 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

529,493

Previous 854,140 38.01%

Holding current value

$11.6 Million

Previous $20.5 Million 38.68%

% of portfolio

0.01%

Previous 0.02%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$20.17 - $23.93 $6.55 Million - $7.77 Million	-324,647 Reduced 38.01%	529,493 $12.6 Million
Q4 2023 Feb 14, 2024	SELL	$19.25 - $24.13 $12.4 Million - $15.6 Million	-645,456 Reduced 43.04%	854,140 $20.5 Million
Q3 2023 Nov 14, 2023	BUY	$19.04 - $22.74 $18.8 Million - $22.4 Million	987,247 Added 192.69%	1,499,596 $32.8 Million
Q2 2023 Aug 14, 2023	SELL	$18.17 - $20.48 $3.29 Million - $3.7 Million	-180,812 Reduced 26.09%	512,349 $9.79 Million
Q1 2023 May 15, 2023	SELL	$16.3 - $19.41 $12.4 Million - $14.7 Million	-758,436 Reduced 52.25%	693,161 $13.5 Million

Q4 2022 Feb 14, 2023	SELL	$14.96 - $17.39 $1.79 Million - $2.08 Million	-119,855 Reduced 7.63%	1,451,597 $23.3 Million
Q3 2022 Nov 14, 2022	SELL	$15.68 - $22.27 $3.25 Million - $4.61 Million	-206,979 Reduced 11.64%	1,571,452 $24.6 Million
Q2 2022 Aug 15, 2022	BUY	$17.44 - $23.16 $9.09 Million - $12.1 Million	521,010 Added 41.43%	1,778,431 $37 Million
Q1 2022 May 16, 2022	SELL	$17.03 - $22.67 $9.09 Million - $12.1 Million	-533,558 Reduced 29.79%	1,257,421 $28.5 Million
Q4 2021 Feb 14, 2022	BUY	$15.84 - $21.88 $16.6 Million - $22.9 Million	1,047,159 Added 140.78%	1,790,979 $32.7 Million
Q3 2021 Nov 15, 2021	BUY	$16.3 - $21.14 $8.33 Million - $10.8 Million	511,317 Added 219.92%	743,820 $15.7 Million
Q2 2021 Aug 16, 2021	SELL	$17.95 - $25.56 $3.8 Million - $5.41 Million	-211,844 Reduced 47.68%	232,503 $4.24 Million
Q1 2021 May 17, 2021	SELL	$20.53 - $25.22 $559,627 - $687,471	-27,259 Reduced 5.78%	444,347 $10 Million
Q4 2020 Feb 16, 2021	SELL	$18.39 - $24.8 $2.31 Million - $3.11 Million	-125,441 Reduced 21.01%	471,606 $9.47 Million
Q3 2020 Nov 16, 2020	BUY	$20.67 - $26.94 $1.12 Million - $1.46 Million	54,275 Added 10.0%	597,047 $14.6 Million
Q2 2020 Aug 14, 2020	SELL	$16.46 - $27.42 $2.42 Million - $4.04 Million	-147,325 Reduced 21.35%	542,772 $12.9 Million
Q1 2020 May 15, 2020	SELL	$14.46 - $21.8 $9 Million - $13.6 Million	-622,535 Reduced 47.43%	690,097 $11.9 Million
Q4 2019 Feb 14, 2020	BUY	$15.15 - $18.89 $7.43 Million - $9.26 Million	490,299 Added 59.62%	1,312,632 $23.1 Million
Q3 2019 Nov 14, 2019	BUY	$17.68 - $22.65 $13.1 Million - $16.7 Million	739,513 Added 892.92%	822,333 $14.5 Million
Q2 2019 Aug 14, 2019	BUY	$18.93 - $24.75 $928,062 - $1.21 Million	49,026 Added 145.07%	82,820 $1.77 Million
Q1 2019 May 15, 2019	SELL	$19.6 - $24.76 $1.63 Million - $2.06 Million	-83,184 Reduced 71.11%	33,794 $804,000
Q4 2018 Feb 14, 2019	SELL	$13.65 - $21.8 $5.54 Million - $8.84 Million	-405,634 Reduced 77.62%	116,978 $2.3 Million
Q3 2018 Nov 14, 2018	SELL	$15.87 - $22.4 $18.8 Million - $26.6 Million	-1,186,999 Reduced 69.43%	522,612 $9.26 Million
Q2 2018 Aug 14, 2018	SELL	$18.56 - $22.45 $829,613 - $1 Million	-44,699 Reduced 2.55%	1,709,611 $36.8 Million
Q1 2018 May 15, 2018	BUY	$22.15 - $31.89 $15.4 Million - $22.2 Million	695,882 Added 65.75%	1,754,310 $38.9 Million
Q4 2017 Feb 14, 2018	SELL	$24.23 - $30.93 $24.6 Million - $31.4 Million	-1,015,258 Reduced 48.96%	1,058,428 $32.2 Million
Q3 2017 Nov 14, 2017	BUY	$23.35 - $29.24 $48.4 Million - $60.6 Million	2,073,686	2,073,686 $50.2 Million

Others Institutions Holding EXEL

# of Institutions

460

Shares Held

246M

Call Options Held

1.7M

Put Options Held

1.02M

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $7.07B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account